CD274 and non-small cell lung carcinoma: We found that Siglec-15/PD-L1 positivity did not alter disease-free survival (DFS) in the entire NSCLC cohort (Fig. S3D, E), a result that may have been influenced by LUSC patients (Fig. S4D, E).